NRG-GU013
Open to Accrual
Protocol Information
Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants
The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer
Principal Investigator
Status
Open to Accrual
Date Opened To Accrual
November 13, 2023
Disease Site
Genitourinary [GU] Prostate
Phase
III
Developmental Therapeutics
No
Primary Objective
To compare metastasis-free survival, determined using
conventional imaging, between men with high-risk prostate cancer randomized to
ultrahypofractionation (SBRT) to those randomized to moderate hypofractionation
and conventional fractionation.
Patient Population
Pathologically proven diagnosis of adenocarcinoma of
prostate cancer and are high-risk disease.
Target Accrual
1209
Protocol Documents
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.
Patient Study Webpage
To learn more about this study, visit the Patient Study Webpage.
-
Share this study.
-
-
-
-
